GSK and Lyell to collaborate on cancer cell therapies

GSK and Lyell Immunopharma have announced a five-year collaboration to develop new technologies with the aim of improving cell therapies for cancer patients. In the announcement the companies explained that the collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including GSK3377794, which targets the NY-ESO-1 antigen that is expressed across multiple

Continue Reading